Cardiff Oncology (CRDF) Earnings Date & Reports

A.I. Advisor

published Earnings

CRDF is expected to report earnings to -25 cents per share on October 31

Cardiff Oncology CRDF Stock Earnings Reports

Q3'24

Est.

$-0.26

Q2'24

Missed

by $0.01

Q1'24

Beat

by $0.03

Q4'23

Beat

by $0.06

Q3'23

Beat

by $0.06

The last earnings report on August 08 showed earnings per share of -25 cents, missing the estimate of -25 cents. With 429.09K shares outstanding, the current market capitalization sits at 128.94M.

View a ticker or compare two or three

Compare

CRDF

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For CRDF
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

11055 Flintkote Avenue

Phone

+1 858 952-7570

Employees

Web

https://www.cardiffoncology.com